{
	"kihkd4aaText": "Bri<span class=\"_ _1\"></span>ntel<span class=\"_ _1\"></span>lix<span class=\"_ _1\"></span>® is ef<span class=\"_ _4\"></span>fect<span class=\"_ _4\"></span>iv<span class=\"_ _1\"></span>e at p<span class=\"_ _1\"></span>rev<span class=\"_ _1\"></span>en<span class=\"_ _1\"></span>ting MD<span class=\"_ _1\"></span>D rela<span class=\"_ _1\"></span>pse <br><span class=\"ls4 wsf\">with<span class=\"_ _4\"></span> long<span class=\"_ _4\"></span>-term<span class=\"_ _4\"></span> bene<span class=\"_ _4\"></span>fit<span class=\"_ _4\"></span>s<span class=\"_ _1\"></span><span class=\"fs3 ls0 v1\">1</span></span>",
	"kihkd4abText": "Study Design",
	"kihkd4acText": "Relapse defined as MADRS total score ≥22 <span class=\"_ _3\"></span>F<span class=\"_ _1\"></span>AS, full analysis set; MADRS, Montgomery-Åsber<span class=\"_ _0\"></span>g Depression Rating Scale",
	"kihkd4adText": "Kaplan–Meier survival analysis of relapse over 24 weeks,<span class=\"_ _1\"></span> ",
	"kihkd4aeText": " <span class=\"_ _46\"></span>after 12 week<span class=\"_ _1\"></span>s of<span class=\"_ _4\"></span> open-label treatment<span class=\"fsb v2\">1</span>",
	"kihkd4afText": "Kaplan–Meier estimate (%)",
	"kihkd4agText": "T<span class=\"_ _1\"></span>re<span class=\"_ _0\"></span>atment week",
	"kihkd4ahText": "Brintellix®<span class=\"_\"> </span>Placebo",
	"kihkd4aiText": "50% <span class=\"ff2 fc2\">fewer patients r<span class=\"_ _0\"></span>elapsed when trea<span class=\"_ _1\"></span>ted with Brintellix® vs placebo<span class=\"fs5 v2\">1 </span></span>",
	"Brintellix_23f1fa72fa": "<span style=\"color: rgb(77, 127, 134); font-family: '15_VDWFON+AvenirNextLTPro-Demi';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_237c097a9f": "<font style=\"font-size: 15px; font-family: '2_VDWFON+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font>",
	"Brintellix_238e01a423": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Boulenger JP et al. J Psychopharmacol 2012;26:1408-1416.</font>",
	"Brintellix_23511ed229": "Text",
	"Brintellix_232b8a5a64": "Text",
	"Brintellix_23f2107a82": "Text",
	"Brintellix_23cdda1bf4": "Text",
	"Brintellix_23d715960d": "Text",
	"Brintellix_23e539e891": "Text",
	"Brintellix_232478a3e5": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;background-color: #e5f0f2;box-sizing: border-box;color: #4d7f86;\">\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">MADRS 10</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Physical symptoms</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Remission</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;color: #fff;background: rgb(233,90,0);background: linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);background: -webkit-linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);\">Relapse prevention</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Short term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Long term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Meta-analysis</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 4px 12px 3px;line-height:1.3;background-color: #e5f0f2;\">Suboptimal responses<br>to SSRI/SNRI</div>\n</div>",
	"Brintellix_23e5f73f1f": "Text"
}
